EZN-2208 (PEG-SN38) Overcomes ABCG2-Mediated Topotecan Resistance in BRCA1-Deficient Mouse Mammary Tumors
Figure 3
Plasma and tumor topotecan pharmacokinetics (PK).
A, Plasma topotecan PK. Abcg2−/− animals, carrying ABCG2-positive tumor T1 (Fig. 2C), were treated with either vehicle +0.5 mg topotecan (green line) or 10 mg Ko143+0.5 mg topotecan (red line) per kg body weight and plasma was collected at 15, 30, 60, 90 and 120 minutes following i.p. injection. Error bars indicate standard deviations of the mean of at least 3 animals per time point. B, Tumor topotecan PK. The tumors of the animals in A were harvested and homogenized to determine topotecan concentrations at the same time points. Error bars indicate standard deviations of the mean of at least 3 animals per time point. P values were calculated using the unpaired t-test.